title: Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy.
abstract: Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics. Interestingly, elevated response rates to these agents are mostly documented among patients with tumors that bear high level of somatic mutations, like melanoma or non-small cell lung carcinoma. We herein formulate the hypothesis that high levels of mutational heterogeneity in the tumor could be the key for the success of immune checkpoint-targeting therapies.
authors.affiliation: Drug Development Department (DITEP); Gustave Roussy; University Paris Sud; Villejuif, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Champiat
authors.affiliation: Department of Medical Oncology; Gustave Roussy; University Paris Sud; Villejuif, France ; INSERM U981; Gustave Roussy; University Paris Sud; Villejuif, France.
authors.forename: Charles
authors.initials: C
authors.lastname: Ferté
authors.affiliation: SIRIC SOCRATE; Gustave Roussy; University Paris Sud; Villejuif, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Lebel-Binay
authors.affiliation: Gustave Roussy; University Paris Sud; Villejuif, France.
authors.forename: Alexander
authors.initials: A
authors.lastname: Eggermont
authors.affiliation: Drug Development Department (DITEP); Gustave Roussy; University Paris Sud; Villejuif, France ; INSERM U981; Gustave Roussy; University Paris Sud; Villejuif, France ; SIRIC SOCRATE; Gustave Roussy; University Paris Sud; Villejuif, France ; Thoracic Multidisciplinary Committee; Gustave Roussy; University Paris Sud; Villejuif, France.
authors.forename: Jean Charles
authors.initials: JC
authors.lastname: Soria
keywords: PD-1; PD-L1; immune checkpoints; immunotherapy; mutational heterogeneity